Osteoarthritis Therapeutics Market worth $11.0 billion by 2025

The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994

“Knee  osteoarthritis therapeutics is expected to hold the largest share of  the osteoarthritis therapeutics market, by anatomy in 2020.”

Based  on anatomy, the market is segmented into knee, hip, hand, and  small-joint osteoarthritis therapeutics. Knee osteoarthritis  therapeutics is the largest and the fastest-growing segment in this  market. This can primarily be attributed to the high incidence of knee  osteoarthritis.

“Viscosupplementation agents is expected to hold the largest share of the osteoarthritis therapeutics market, in 2020.”

Based  on drug type, the market is classified as, viscosupplementation agents,  nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and  corticosteroids. The analgesics segment is subsegmented into duloxetine  and acetaminophen, while the NSAIDs segment is subsegmented into  naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The  viscosupplementation agents segment accounted for the largest share of  the osteoarthritis therapeutics market in 2019. The rising incidence of  knee osteoarthritis is the major factor driving the growth of this  segment. Viscosupplementation effectively eases the pain of  osteoarthritis through injections that fill up the joint’s synovial  fluid, thus offering better lubrication of the joints.

“Parental route is expected to hold the largest share of the osteoarthritis therapeutics market in 2020.”

On  the basis of route of administration, the osteoarthritis therapeutics  market has been segmented into oral, topical, and parenteral routes. The  parenteral route accounted for the largest share of this market in 2019  and is estimated to grow at the highest CAGR during the forecast  period. This can be attributed to the wide adoption of the parenteral  route for administering osteoarthritis therapeutics owing to the ease of  administration and the better pharmacokinetics and pharmacodynamics,  resulting in better patient compliance.

“Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”

Based  on the distribution channel, the osteoarthritis therapeutics market is  segmented into hospital pharmacies, online pharmacies, and retail  pharmacies. In 2019, hospital pharmacies accounted for the largest share  of this market because of the high volume of patients visiting  hospitals for osteoarthritis treatments and the wide range of  osteoarthritis therapeutics available in these pharmacies.  Reimbursements can also be claimed easily on hospital pharmacy  purchases, which is another important draw.

“Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”

Based  on the purchasing pattern, the osteoarthritis therapeutics market is  segmented into OTC and prescription drugs. In 2019, the prescription  drugs segment accounted for a larger share of this market as most  osteoarthritis therapeutics (viscosupplementation agents and  corticosteroids) are only available on prescription.

“Europe commanded the largest share of the osteoarthritis therapeutics market in 2020.”

On  the basis of region, the osteoarthritis therapeutics market is  segmented into North America, Europe, Asia Pacific, and the Rest of the  World. In 2019, Europe commanded the largest share of the osteoarthritis  therapeutics market. The large share of this market segment can be  attributed to the rising incidence of osteoarthritis, rising geriatric  population, and increasing obesity rates in several European countries,  coupled with the rising number of injuries due to sports and road  accidents.

The  major players operating in this market are Sanofi (France), Horizon  Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline  PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly  (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring  Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings,  Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc.  (US), Pharmed Limited (India), Virchow Biotech (India), Kitov  Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs  (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi  Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).